Joshua Christensen, MD
Infectious Disease · Missoula, MTNPI 1316093917
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $182 of the $281 with a category attached, or 64.7%. 3 manufacturers reported payments, led by Medtronic at 46.8% of the total. Reporting peaked in 2022 at $131 and has fallen 79.1% since, to $27 in 2024.
Across 4 payments — averaging $70.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$131
- Insmed, Inc.$122
- AbbVie$27
Across 9 payments — averaging $12,088 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$104K
- Janssen Research & Development, LLC$5K
What the payments were for
- Food & beverage$18265%
- Education$9935%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 1 | $131 |
| Insmed, Inc. | 2 | $122 |
| AbbVie | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$281 in reported general payments places this provider in the 75th percentile of 22 infectious disease providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $54,466 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 11 | $44,020 |
| Fluconazole | 14 | $1,991 |
| CefuroximeCefuroxime Axetil | 30 | $1,593 |
| Cefadroxil | 46 | $1,426 |
| Doxycycline Hyclate | 49 | $1,013 |
| Cefazolin Sodium | 12 | $756 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 21 | $606 |
| Amoxicillin | 28 | $420 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 19 | $152 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Missoula
- Marco LorioMissoula$533
- Leslie WhitneyMissoula$233
- David ChristiansenMissoula$126
- Claude TonnerreMissoula$0
- Jeffrey TjadenBozeman$2K
- Nabiya SiddiquiGreat Falls$1K
- Benedict PainterBozeman$1K
- Tsun Sheng KuBillings$1K
- Elias BaiedGreat Falls$262
- Raymond GeyerGreat Falls$207
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.